CO6280479A2 - Dronedarona para la prevencion de la fibrilacion auricular permamente - Google Patents
Dronedarona para la prevencion de la fibrilacion auricular permamenteInfo
- Publication number
- CO6280479A2 CO6280479A2 CO10154617A CO10154617A CO6280479A2 CO 6280479 A2 CO6280479 A2 CO 6280479A2 CO 10154617 A CO10154617 A CO 10154617A CO 10154617 A CO10154617 A CO 10154617A CO 6280479 A2 CO6280479 A2 CO 6280479A2
- Authority
- CO
- Colombia
- Prior art keywords
- heart
- atrial fibrillation
- dronedarone
- age
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Furan Compounds (AREA)
Abstract
La presente invención se refiere al uso de dronedarona para la preparación de un medicamento para uso en la prevención de la fibrilación auricular permanente.El 2-n-Butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamidobenzofurano, o dronedarona, y sus sales aceptables farmacéuticamente se describen en la Patente Europea EP 0471 609 B1.La dronedarona es un bloqueante multicanal que ejerce influencia sobre los canales de calcio, potasio y sodio y tiene propiedades anti-adrenérgicas.La dronedarona es un agente anti-arrítmico para el tratamiento de pacientes con un historial de fibrilación auricular o aleteo auricular.La fibrilación auricular (AF) afecta aproximadamente a 2,3 millones de personas en Norte América y 4,5 millones de personas en la Unión Europea y está emergiendo como un problema de salud pública creciente a causa de la edad de la población.AF es una afección en la que las cámaras superiores del corazón laten de forma descoordinada y desorganizada, dado como resultado un ritmo muy irregular y rápido (es decir, un latido del corazón irregularmente irregular). Cuando la sangre no se bombea completamente fuera de las cámaras del corazón, puede encharcarse y formar coágulos. Si un coágulo de sangre se forma en la aurícula, sale del corazón y bloquea una arteria en el cerebro, se produce un ictus. Consecuentemente, aproximadamente el 15 por ciento de los ictus son resultado de AF.AF cada vez más frecuente con el aumento de edad y a menudo está causado por cambios en el corazón relacionados con la edad, estrés físico o psicológico, agentes que estimulan el corazón, tal como la cafeína, o como resultado de una enfermedad cardiovascular. Se espera que el número sea el doble en los próximos 20 años. Sin una gestión apropiada, AF puede conducir a complicaciones serias, tales como ictus y fallo cardiaco congestivo.Se sabe que la fibrilación auricular por sí misma puede causar cambios de los parámetros eléctricos del corazón, conocidos como remodelado eléctrico y en la estructura de las cámaras cardiacas conocido como remodelado estructural, lo que tiende a disminuir las oportunidades del paciente de volver a su ritmo sinusal normal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6026308P | 2008-06-10 | 2008-06-10 | |
| EP08290531A EP2133074A1 (en) | 2008-06-10 | 2008-06-10 | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6280479A2 true CO6280479A2 (es) | 2011-05-20 |
Family
ID=39731657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10154617A CO6280479A2 (es) | 2008-06-10 | 2010-12-09 | Dronedarona para la prevencion de la fibrilacion auricular permamente |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20110166220A1 (es) |
| EP (2) | EP2133074A1 (es) |
| JP (1) | JP2011522876A (es) |
| KR (1) | KR20110026422A (es) |
| CN (1) | CN102056603A (es) |
| AR (1) | AR072069A1 (es) |
| AU (1) | AU2009259009A1 (es) |
| CA (1) | CA2727326A1 (es) |
| CL (1) | CL2010001422A1 (es) |
| CO (1) | CO6280479A2 (es) |
| CR (1) | CR11829A (es) |
| DO (1) | DOP2010000365A (es) |
| EA (1) | EA201071378A1 (es) |
| EC (1) | ECSP10010666A (es) |
| IL (1) | IL209791A0 (es) |
| MA (1) | MA32462B1 (es) |
| MX (1) | MX2010013698A (es) |
| NI (1) | NI201000211A (es) |
| PE (1) | PE20110055A1 (es) |
| SV (1) | SV2010003756A (es) |
| TW (1) | TW201002676A (es) |
| UY (1) | UY31886A (es) |
| WO (1) | WO2009150535A1 (es) |
| ZA (1) | ZA201008871B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102065855A (zh) | 2008-04-17 | 2011-05-18 | 赛诺菲-安万特 | 决奈达隆在制备用于预防因心血管疾病住院或死亡的药物中的用途 |
| FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
| EP2116239A1 (en) * | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
| AU2014274638B2 (en) * | 2009-12-21 | 2016-09-15 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
| TWI508726B (zh) * | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| WO2011141888A1 (en) * | 2010-05-13 | 2011-11-17 | Sanofi | Use of dronedarone for the preparation of a medicament for the prevention of cardiovacular hospitalizations or death or cardiovascular events in patients with permanent atrial fibrillation |
| EP2387996A1 (en) * | 2010-05-17 | 2011-11-23 | Sanofi | Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation |
| EP2387997A1 (en) * | 2010-05-18 | 2011-11-23 | Sanofi | Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients who developed permanent atrial fibrillation throughout the period the dronedarone is administered |
| US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
| WO2012020377A1 (en) * | 2010-08-11 | 2012-02-16 | Sanofi | Use of dronedarone for the preparation of a medicament for rhythm- and rate-controlling in patients with atrial fibrillation |
| WO2012023024A2 (en) * | 2010-08-17 | 2012-02-23 | Lupin Limited | Controlled release formulations of dronedarone |
| EP3326616B1 (en) * | 2011-06-03 | 2021-07-28 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
| EP2543363A1 (en) * | 2011-07-07 | 2013-01-09 | Sanofi | Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts |
| EP2543362A1 (en) * | 2011-07-07 | 2013-01-09 | Sanofi | Sustained release pharmaceutical oral solid dosage form of dronedarone or one of its pharmaceutically acceptable salts |
| EP2543361A1 (en) * | 2011-07-07 | 2013-01-09 | Sanofi | Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts |
| FR2977495B1 (fr) * | 2011-07-07 | 2014-03-07 | Sanofi Sa | Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation |
| WO2013024411A1 (en) | 2011-08-12 | 2013-02-21 | Lupin Limited | Co-milled formulation of dronedarone |
| CN112336445B (zh) * | 2019-12-26 | 2021-11-26 | 上海微创电生理医疗科技股份有限公司 | 一种消融系统及其神经探测设备 |
-
2008
- 2008-06-10 EP EP08290531A patent/EP2133074A1/en not_active Withdrawn
-
2009
- 2009-06-08 CA CA2727326A patent/CA2727326A1/en not_active Abandoned
- 2009-06-08 CN CN2009801219070A patent/CN102056603A/zh active Pending
- 2009-06-08 PE PE2010001117A patent/PE20110055A1/es not_active Application Discontinuation
- 2009-06-08 JP JP2011513071A patent/JP2011522876A/ja not_active Withdrawn
- 2009-06-08 WO PCT/IB2009/006106 patent/WO2009150535A1/en active Application Filing
- 2009-06-08 MX MX2010013698A patent/MX2010013698A/es not_active Application Discontinuation
- 2009-06-08 EA EA201071378A patent/EA201071378A1/ru unknown
- 2009-06-08 KR KR1020107027660A patent/KR20110026422A/ko not_active Application Discontinuation
- 2009-06-08 EP EP09762063A patent/EP2300001A1/en not_active Withdrawn
- 2009-06-08 AU AU2009259009A patent/AU2009259009A1/en not_active Abandoned
- 2009-06-08 AR ARP090102050A patent/AR072069A1/es unknown
- 2009-06-10 UY UY0001031886A patent/UY31886A/es not_active Application Discontinuation
- 2009-06-10 TW TW098119393A patent/TW201002676A/zh unknown
-
2010
- 2010-11-29 DO DO2010000365A patent/DOP2010000365A/es unknown
- 2010-12-06 NI NI201000211A patent/NI201000211A/es unknown
- 2010-12-06 IL IL209791A patent/IL209791A0/en unknown
- 2010-12-07 US US12/962,102 patent/US20110166220A1/en not_active Abandoned
- 2010-12-07 CR CR11829A patent/CR11829A/es not_active Application Discontinuation
- 2010-12-08 EC EC2010010666A patent/ECSP10010666A/es unknown
- 2010-12-09 CO CO10154617A patent/CO6280479A2/es not_active Application Discontinuation
- 2010-12-09 ZA ZA2010/08871A patent/ZA201008871B/en unknown
- 2010-12-09 SV SV2010003756A patent/SV2010003756A/es unknown
- 2010-12-10 CL CL2010001422A patent/CL2010001422A1/es unknown
-
2011
- 2011-01-07 MA MA33501A patent/MA32462B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009150535A1 (en) | 2009-12-17 |
| AU2009259009A1 (en) | 2009-12-17 |
| EP2300001A1 (en) | 2011-03-30 |
| SV2010003756A (es) | 2011-03-15 |
| UY31886A (es) | 2010-01-29 |
| CR11829A (es) | 2011-01-11 |
| JP2011522876A (ja) | 2011-08-04 |
| IL209791A0 (en) | 2011-02-28 |
| DOP2010000365A (es) | 2011-01-15 |
| NI201000211A (es) | 2011-04-27 |
| ZA201008871B (en) | 2012-02-29 |
| PE20110055A1 (es) | 2011-02-11 |
| EP2133074A1 (en) | 2009-12-16 |
| ECSP10010666A (es) | 2011-01-31 |
| CA2727326A1 (en) | 2009-12-17 |
| CL2010001422A1 (es) | 2011-05-13 |
| KR20110026422A (ko) | 2011-03-15 |
| US20110166220A1 (en) | 2011-07-07 |
| MA32462B1 (fr) | 2011-07-03 |
| TW201002676A (en) | 2010-01-16 |
| EA201071378A1 (ru) | 2011-06-30 |
| WO2009150535A8 (en) | 2010-12-23 |
| CN102056603A (zh) | 2011-05-11 |
| AR072069A1 (es) | 2010-08-04 |
| MX2010013698A (es) | 2011-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6280479A2 (es) | Dronedarona para la prevencion de la fibrilacion auricular permamente | |
| Sodi-Pallares et al. | The polarizing treatment of acute myocardial infarction: possibility of its use in other cardiovascular conditions | |
| UY28090A1 (es) | Derivados de acido mandelico | |
| EA201491433A1 (ru) | Синтетические миметики апелина для лечения сердечной недостаточности | |
| CU20160013A7 (es) | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardíaca | |
| NO20084355L (no) | N-hydroksylsulfonamidderivater som nye fysiologisk anvendelige nitroksyldonorer | |
| EA200601765A1 (ru) | Новые антиаритмические лекарственные средства и лекарственные средства, применяемые при сердечной недостаточности, нацеленные на утечку в рецепторе рианодина (ryr2), и их применение | |
| PE20142193A1 (es) | Agentes para tratar trastornos que implican la modulacion de receptores de rianodina | |
| NO20076121L (no) | Behandlinger for kardiovaskulaer sykdom | |
| Lippestad et al. | Sinus arrest in proximal right coronary artery occlusion | |
| ECSP055914A (es) | Combinación farmacéutica para la prevención o la terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales | |
| KR20110042344A (ko) | 뇌졸중 또는 일과성 허혈 발작을 예방하기 위한 약제의 제조에서의 드로네다론의 용도 | |
| CO6280478A2 (es) | Dronedarona para la prevencion de la cardioversion | |
| Kong et al. | Intramural optical mapping of V m and Cai2+ during long-duration ventricular fibrillation in canine hearts | |
| RU2009110449A (ru) | Ингибиторы мутантной формы киназы kit | |
| NO20070148L (no) | Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen | |
| Arias et al. | Atrial fibrillation and obstructive sleep apnea: something more than a coincidence | |
| NO20070147L (no) | Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen | |
| Humphreys et al. | Arrhythmias and their Management | |
| Borghi et al. | Omega-3 fatty acids: A promising possible treatment for Meniere’s Disease and other inner ear disorders of unknown origin? | |
| Chung et al. | Fatal cardiac thromboembolism in a patient with a pacemaker during ureteroscopic lithotripsy for ureter stone: a case report | |
| Sen et al. | Phrenic Nerve Injury-a Commonly Missed Diagnosis | |
| Sadeghian et al. | Short QT syndrome and idiopathic ventricular tachycardia in a 28-year-old young man: a potential disease-specific link? | |
| Değirmencioğu et al. | A rare manifestation of atrial fibrillation in the presence of Wolff-Parkinson-White syndrome: tachycardia-induced cardiomyopathy | |
| SE0101328D0 (sv) | Therapeutic treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |